1263 related articles for article (PubMed ID: 19158438)
21. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Konstandelou E; Tolis G
Pediatr Hematol Oncol; 2007; 24(7):481-91. PubMed ID: 17786784
[TBL] [Abstract][Full Text] [Related]
22. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
[TBL] [Abstract][Full Text] [Related]
23. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
[TBL] [Abstract][Full Text] [Related]
24. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
25. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration.
Marini H; Minutoli L; Polito F; Bitto A; Altavilla D; Atteritano M; Gaudio A; Mazzaferro S; Frisina A; Frisina N; Lubrano C; Bonaiuto M; D'Anna R; Cannata ML; Corrado F; Cancellieri F; Faraci M; Marini R; Adamo EB; Wilson S; Squadrito F
J Bone Miner Res; 2008 May; 23(5):715-20. PubMed ID: 18433304
[TBL] [Abstract][Full Text] [Related]
26. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
[TBL] [Abstract][Full Text] [Related]
27. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
28. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
30. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
31. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction.
Briana DD; Boutsikou M; Baka S; Hassiakos D; Gourgiotis D; Malamitsi-Puchner A
Neonatology; 2009; 96(2):132-6. PubMed ID: 19365143
[TBL] [Abstract][Full Text] [Related]
32. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.
Abdallah BM; Stilgren LS; Nissen N; Kassem M; Jørgensen HR; Abrahamsen B
Calcif Tissue Int; 2005 Feb; 76(2):90-7. PubMed ID: 15570403
[TBL] [Abstract][Full Text] [Related]
33. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
34. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
[TBL] [Abstract][Full Text] [Related]
35. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
36. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
Rhee EJ; Oh KW; Lee WY; Kim SY; Oh ES; Baek KH; Kang MI; Kim SW
Am J Obstet Gynecol; 2005 Apr; 192(4):1087-93. PubMed ID: 15846185
[TBL] [Abstract][Full Text] [Related]
37. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
39. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis.
González-Calvin JL; Mundi JL; Casado-Caballero FJ; Abadia AC; Martin-Ibañez JJ
J Clin Endocrinol Metab; 2009 Dec; 94(12):4844-50. PubMed ID: 19897681
[TBL] [Abstract][Full Text] [Related]
40. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
